Cosciens Biopharma (OTCPK:CSCIF) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Cosciens Biopharma Effective Interest Rate on Debt % Related Terms
Cosciens Biopharma Effective Interest Rate on Debt % Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma Effective Interest Rate on Debt % Chart
CSCIF vs VRTX, REGN, ALNY: Effective Interest Rate on Debt % Comparison
For the Biotechnology subindustry, Cosciens Biopharma's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Effective Interest Rate on Debt % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Effective Interest Rate on Debt % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
What does a Effective Interest Rate on Debt % of 8.82% mean?
Cosciens Biopharma (CSCIF) has a Effective Interest Rate on Debt % of 8.82% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Cosciens Biopharma and its competitors.
Is Cosciens Biopharma's Effective Interest Rate on Debt % too high?
Cosciens Biopharma's current Effective Interest Rate on Debt % is 8.82%. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Effective Interest Rate on Debt % compare to VRTX and REGN?
Cosciens Biopharma's Effective Interest Rate on Debt % of 8.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current Effective Interest Rate on Debt % is 8.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Fairly Valued. The stock's GF Value™ is $2.34, compared to a current price of $2.29 — trading 2.1% below its estimated fair value. The current Effective Interest Rate on Debt % is 8.82%. Cosciens Biopharma's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Effective Interest Rate on Debt % is 8.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $2.29 is trading 2.1% below its estimated GF Value™ of $2.34.
GuruFocus considers Cosciens Biopharma to be Fairly Valued.
Key valuation signals for CSCIF:
Effective Interest Rate on Debt %: 8.82%
GF Value™: $2.34 vs. price of $2.29 (2.1% below fair value)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score
Get the complete analysis for CSCIF
Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
